

Summary under Regulation 13(1B) of the Competition Commission of India (Procedure in regard to the transaction of business relating to combinations) Regulations, 2011

A. Name of the parties

The parties to the Combination are DiaSys Diagnostics India Private Limited ("**DiaSys India**") and Piramal Enterprises Limited ("**Piramal**")

B. Type of Combination

The transaction relates to the acquisition of the 'lab diagnostics and point of care' business of Piramal by DiaSys India on a slump sale basis. The transaction has been effected through a Sale and Purchase Agreement ("**SPA**") and Technology Assignment Agreement ("**TAA**") both dated 15th September 2014. Neither party holds any shares in the other party or has any control over the other party, at any time, prior to or post consummation of this transaction. It was merely the transfer of a loss making business unit (its assets, employees, records, etc.) from Piramal to the newly created DiaSys India.

C. Area of Activity of the Parties

1. After the execution of the SPA and TAA, DiaSys India commenced its business of manufacturing and marketing a wide range of point of care diagnostic solutions and reagents. DiaSys India is a wholly owned subsidiary of DiaSys Diagnostics Systems GmbH, Germany.

2. Piramal is the flagship company of the Piramal Group, an Indian conglomerate with a wide range of businesses ranging from healthcare products, pharma solutions, financial services and information management.

D. Relevant Market

1. For the purpose of the acquisition, the relevant market would be as follows:
 - a) The market for point of care diagnostic equipment in India; and
 - b) The market for diagnostic reagents in India.